Key points are not available for this paper at this time.
Improved glycemic control of type 2 DM is associated with substantial short-term symptomatic, QOL, and health economic benefits.
Testa et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: